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Abstract: The activation of L-type calcium channels (LTCCs) prevents cerebellar granule neurons
(CGNs) from entering low-K+-induced apoptosis. In previous works, we showed that LTCCs are
largely associated with caveolin-1-rich lipid rafts in the CGN plasma membrane. In this work,
we show that protein kinase A (PKA) and calmodulin-dependent protein kinase II (CaMK-II) are
associated with caveolin-1-rich lipid rafts of mature CGNs, and we further show that treatment
with the cholesterol-trapping and lipid raft-disrupting agent methyl-β-cyclodextrin decreases the
phosphorylation level of the LTCC β2 subunit and the steady-state calcium concentration in neuronal
somas ([Ca2+]i) to values close to those measured in 5 mM KCl proapoptotic conditions. These
effects correlate with the effects produced by a short (15 min) treatment of CGNs with H-89 and
KN-93—inhibitors of PKA and CaMK-II, respectively—in 25 mM KCl medium. Moreover, only a
15 min incubation of CGNs with H-89 produces about a 90% inhibition of the calcium entry that
would normally occur through LTCCs to increase [Ca2+]i upon raising the extracellular K+ from 5 to
25 mM, i.e., from proapoptotic to survival conditions. In conclusion, the results of this work suggest
that caveolin-1-rich lipid rafts play a major role in the control of the PKA- and CaMK-II-induced
phosphorylation level of the LTCC β2 subunit, thus preventing CGNs from entering apoptosis.
Keywords: β2 subunit of L-type calcium channels; cholesterol depletion; caveolin-1-rich lipid rafts;
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1. Introduction
Cyclodextrins are used as additives to improve the aqueous solubility of poorly soluble drugs
and increase their bioavailability [1], and they are being increasingly used in nanoparticle-based
drug delivery [2]. Cyclodextrins are also used as anti-browning agents in different foods and
foodstuffs [3]. However, a link between cyclodextrins and iatrogenic hearing loss has been noted in
several species, including humans [4]. In particular, methyl-β-cyclodextrin has been widely used for
the selective removal of cholesterol and disruption of lipid rafts in different cell lines (see, e.g., [5,6]).
The neurological risks of using methyl-β-cyclodextrin are informed by the reported toxicity of this
compound to neuronal cell lines [7]. Thus, the molecular mechanism underlying selective neuronal
cell death induced by methyl-β-cyclodextrin deserves to be studied.
L-type calcium channels (LTCCs) together with N-methyl D-aspartate receptors (NMDAr),
plasma membrane Ca2+-ATPase (PMCA), and sodium calcium exchangers are associated with the
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cholesterol and caveolin-1-rich lipid raft nanodomains of the cerebellar granule neuron (CGN)
plasma membrane [8–10], thereby inducing high calcium transients near these nano-transducer
domains that potentiate faster and stronger Ca2+-mediated neuronal responses to external stimulus.
The pore-forming α1 subunits (from CaV1.1 to CaV1.4) determine the electrophysiological and
pharmacological properties of LTCCs, but auxiliary subunits (β1–4, α2-δ and γ) modulate their
trafficking, surface expression, and biophysical properties [11–13]. β subunits have been shown to serve
as scaffolding proteins that bind AHNAKs to link voltage-gated calcium channels (VGCCs) to the actin
cytoskeleton [14]. In a previous work, we showed that disruption of the actin cytoskeleton in cultured
CGNs exposed to 3-morpholinosydnonimine-oxidative stress is linked to alterations of the cytosolic
calcium concentration [15]. Notably, both protein kinase A (PKA) and calcium/calmodulin-dependent
protein kinase II (CaMK-II) are also associated with cytoskeleton elements near the plasma membrane.
Razani and colleagues demonstrated the colocalization and direct interaction between the caveolin-1
scaffolding domain and the catalytic subunit of PKA in vitro and in vivo [16]. Further, in the brain, the
association of PKA with the LTCC CaV1.2 (α1C) subunit was demonstrated [17]. Several works have
reported that CaMK-II interacts with LTCCs and NMDAr [18–20]. Moreover, it has been suggested
that a direct association exists between CaMK-II and lipid rafts [21], as well as a colocalization
between LTCC (CaV1.2) and CaMK-II [22]. LTCC modulation by PKA is due to β2 and CaV1.2 (α1C)
subunit phosphorylation [23,24]. Mutations of serine 478 (Ser478) and serine 479 (Ser479) in the β2
subunit were shown to completely inhibit the increase in calcium currents through LTCCs induced
by PKA [23]. LTCC modulation by CaMK-II plays a major role in the calcium-dependent facilitation
of these calcium channels [25,26]. Moreover, the association of CaMK-II with the LTCC β subunit
facilitates the interaction of CaMK-II with additional domains of the α1 subunit [25] and can enhance
phosphorylation by CaMK-II at Thr498 and other residues of the β2a subunit [27]. Of significant note
are reports that the deregulation of lipid raft-dependent signaling is likely to play a major role in
neurodegenerative diseases characterized by alterations of cholesterol and ganglioside composition,
such as Alzheimer’s, Parkinson’s, and other age-related diseases [28–31].
The control of cytosolic calcium is a key factor for cell survival [32]. In primary cultures of
mature cerebellar granule neurons (CGNs), the entry of calcium through L-type calcium channels
(LTCCs) plays a major role in maintaining cytosolic calcium homeostasis within the survival
concentration range [33–35]. Lowering the extracellular potassium concentration to 5 mM leads
to a slowly developing apoptotic process in CGNs cultured with a sustained low level of [Ca2+]i [33].
Activation of voltage-operated Ca2+ channels has been shown to account for most of the increase
in [Ca2+]i observed in CGNs upon partial depolarization by increasing KCl concentration to
25 mM [33,36–38]; this dependency also explains the proapoptotic effects of blocking LTCCs by
nifedipine or nimodipine [33]. In addition, PKA and CaMK have been reported to play a major role
in the protection against low-potassium-induced CGN apoptosis in vitro. Cyclic AMP is protective
against apoptosis: when apoptosis is induced by shifting cultures to low potassium, cAMP activates
cAMP-dependent PKA [39–42]. CaMK-mediated activation of the protein kinase B pathway promotes
CGN survival [43], and it has been shown that calcium entry through LTTCs, which protects
cells from low-potassium-induced apoptosis, potentiates the activity of calcium/calmodulin kinase
IV (CaMK-IV), preventing caspase 3-dependent cleavage of CaMK-IV, which in turn maintains a
survival–favoring level of CREB-dependent gene expression [44]. However, in previous works, the
possibility that the protective effects afforded by PKA and CaMK activities were, at least in part,
accounted for by phosphorylation-dependent modulation of LTCCs has not been considered, to the
best of our knowledge, and deserves to be studied.
On these grounds, the major aims of this work are to study in mature CGNs cultured on a
chemically defined medium: (i) the effect of the lipid raft-disrupting agent methyl-β-cyclodextrin
(MβCD) on the phosphorylation level of the β2 subunit of LTTCs and on the steady-state cytosolic
calcium concentration; (ii) the phosphorylation level of the β2 subunit of LTTCs in 25 mM KCl medium,
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in proapoptotic 5 mM KCl medium, and in the presence of PKA and CaMK-II inhibitors; and (iii) the
effect of inhibitors of PKA and CaMK-II on the steady-state cytosolic calcium concentration.
2. Results
2.1. Treatment of CGNs with MβCD Decreases the Phosphorylation Level of the β2 Subunit of LTCC
The experimental conditions for significant cholesterol sequestration by MβCD were fixed in
this work while taking into account the average duration of the CGN treatments with protein kinase
inhibitors (15 min) plus the time for the acquisition of 340/380 ratio images (5 min). Thus, we incubated
the CGNs with different concentrations of MβCD at 37 ◦C for 20 min, followed by removal of the
medium to analyze the cholesterol content of neurons. The results shown in Table 1 demonstrate that
a 20 min exposure of CGNs to 10 mM MβCD at 37 ◦C is enough to reduce their cholesterol content
from 22.8 ± 2.1 to 4.6 ± 0.4 nmol cholesterol/mg of CGN protein, i.e., more than an 80% reduction
in the cholesterol content of CGNs. These results also point out that the maximum sequestration of
cholesterol from these cells is obtained with 10 mM MβCD under experimental conditions that do
not produce a significant loss of cell viability after 20 min (Table 1). Indeed, concentrations of MβCD
higher than 20 mM were needed to observe a significant loss of cell viability within this time period.
These experimental conditions are similar to those used in a previous work, where we showed that a
large impairment of the NMDAr response to L-glutamate is induced by MβCD treatment in mature
CGNs [9].
Treatment with MβCD largely alters the phosphorylation levels of LTCCs in CGNs (Figure 1).
Compared to the control conditions (K25), treatment with 1 and 5 mM MβCD decreases the
phosphorylation level of the β2 subunit of LTCCs by 60–70%.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 21 
 
 
Figure 1. MβCD decreases the phosphorylation level of the β2 subunit of L-type calcium channels 
(LTCCs). The phosphorylation level of the β2 subunit of LTCCs was measured by Western blotting, 
as indicated below, after the incubation of CGNs in MLocke’s K25 plus 1 or 5 mM of MβCD for 15 
min at 37 °C in a 5% CO2 culture chamber. After SDS-PAGE (7.5% acrylamide), the proteins were 
transferred to PVDF membranes for Western blotting, as indicated in the Materials and Methods. The 
positions of the molecular weight marker bands closest to the target proteins of the primary 
antibodies, i.e., β2 subunit of LTCCs, LTCC α1C subunit, and β-actin, are shown at the left or right side 
of the corresponding PVDF membrane images. The phosphorylation levels of the β2 subunit of 
LTCCs, (p)β2LTCC/LTCC, were measured using the ratio between the intensities of the ~73 and ~174 
kDa bands obtained with rabbit antibodies: PCCb2-140AP (FabGennix Inc., Frisco, TX, USA)—
dilution 1:100 [(p)β2LTCC]—and anti-LTCC-α1C-subunit (Santa Cruz Biotechnology, Heidelberg, 
Germany, sc-25686)—dilution 1:100 [LTCC], respectively. For quantification of the ratio 
(p)β2LTCC/LTCC, the intensities of the bands were normalized first to the intensities of their 
corresponding ~42 kDa anti-β-actin bands (mouse anti-β-actin A1978, 0.75 µg/mL) as the internal 
control of protein loading. See Materials and Methods for other experimental details. Images shown 
are representative of the results obtained in experiments done with at least three different CGN 
preparations. The average results ± S.E. of triplicate experiments are presented as a bar plot. (*) p < 0.05. 
2.2. PKA and CaMK-II Are Associated with Caveolin-1-Rich Lipid Rafts in the Plasma Membrane of CGNs 
To evaluate the relative distribution of proteins between lipid raft and non-lipid raft membrane 
fractions, we experimentally assessed: (1) the presence of PKA and CaMK-II in caveolin-1-rich lipid 
rafts prepared from of mature CGNs in culture and (2) the percentage of immunoprecipitation of 
PKA and CaMK-II with caveolin-1 in cell lysates treated with 1% Triton X-100. 
Lipid rafts were prepared as indicated in the Materials and Methods section from mature CGNs 
in MLocke’s K5 (proapoptotic conditions) and also in partially depolarizing plasma membrane 
media, K25 (survival conditions). Lipid raft fractions were characterized using H-Ras, caveolin-1, and 
flotillin as protein markers, as in previous works [8–10]. Western blots of lipid raft fractions show 
that PKA and CaMK-II are present in lipid rafts prepared from CGNs in MLocke’s K5 and K25 (Figure 
2A). Note, however, that these protein kinases are not only present in the lipid raft fractions, since 
PKA and CaMK-II are also present in other membrane fractions. 
Fig re 1. t phos r l ti l l of the β2 s i f L-ty e calciu channels
(LTCCs). The phosphorylation level of the β2 subunit of LTC s was measured by West rn blotting, as
ind cated below, after the incubation of CGNs in MLocke’s K25 plus 1 or 5 mM of MβCD for 15 min at
37 ◦C in a 5% CO2 culture chamber. After SDS-PAGE (7.5% acrylamide), the prot ins were transferr d
to PVDF membranes for Western blotting, as indicated in the Materials and M thods. The positions of
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the molecular weight marker bands closest to the target proteins of the primary antibodies, i.e.,
β2 subunit of LTCCs, LTCC α1C subunit, and β-actin, are shown at the left or right side of the
corresponding PVDF membrane images. The phosphorylation levels of the β2 subunit of LTCCs,
(p)β2LTCC/LTCC, were measured using the ratio between the intensities of the ~73 and ~174 kDa
bands obtained with rabbit antibodies: PCCb2-140AP (FabGennix Inc., Frisco, TX, USA)—dilution
1:100 [(p)β2LTCC]—and anti-LTCC-α1C-subunit (Santa Cruz Biotechnology, Heidelberg, Germany,
sc-25686)—dilution 1:100 [LTCC], respectively. For quantification of the ratio (p)β2LTCC/LTCC,
the intensities of the bands were normalized first to the intensities of their corresponding ~42 kDa
anti-β-actin bands (mouse anti-β-actin A1978, 0.75 µg/mL) as the internal control of protein loading.
See Materials and Methods for other experimental details. Images shown are representative of the
results obtained in experiments done with at least three different CGN preparations. The average
results ± S.E. of triplicate experiments are presented as a bar plot. (*) p < 0.05.
Table 1. A short-term incubation with methyl-β-cyclodextrin (MβCD) efficiently extracts cholesterol
from cerebellar granule neurons (CGNs) while preserving cell viability.
[MβCD] (mM) Cholesterol Content (nmol/mg of CGN Protein) Cell Viability
0 22.8 ± 2.1 100 ± 5%
5 8.4 ± 0.9 100 ± 5%
10 4.6 ± 0.4 100 ± 6%
20 4.7 ± 0.4 95 ± 5%
2.2. PKA and CaMK-II Are Associated with Caveolin-1-Rich Lipid Rafts in the Plasma Membrane of CGNs
To evaluate the relative distribution of proteins between lipid raft and non-lipid raft membrane
fractions, we experimentally assessed: (1) the presence of PKA and CaMK-II in caveolin-1-rich lipid
rafts prepared from of mature CGNs in culture and (2) the percentage of immunoprecipitation of PKA
and CaMK-II with caveolin-1 in cell lysates treated with 1% Triton X-100.
Lipid rafts were prepared as indicated in the Materials and Methods section from mature CGNs
in MLocke’s K5 (proapoptotic conditions) and also in partially depolarizing plasma membrane media,
K25 (survival conditions). Lipid raft fractions were characterized using H-Ras, caveolin-1, and flotillin
as protein markers, as in previous works [8–10]. Western blots of lipid raft fractions show that PKA
and CaMK-II are present in lipid rafts prepared from CGNs in MLocke’s K5 and K25 (Figure 2A).
Note, however, that these protein kinases are not only present in the lipid raft fractions, since PKA and
CaMK-II are also present in other membrane fractions.
Immunoprecipitation of cell lysates with caveolin-1 was carried out as indicated in the Materials
and Methods section, and the results are presented in image and table format in Figure 2B. The results
show that both PKA and CaMK-II coimmunoprecipitate with anti-caveolin-1. The intensity of Western
blot bands was calculated for the whole immunoprecipitate and supernatant fractions to calculate
the percentage of PKA and CaMK-II present in the total cell lysate that is bound to caveolin-1 or to
proteins associated with caveolin-1. These results also highlight that CaMK-II has a higher percentage
of coimmunoprecipitation with caveolin-1 (39 ± 5%) than PKA (16 ± 2%).
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Figure 2. Protein kinase A (PKA) and calmodulin-dependent protein kinase II (CaMK-II) are 
associated with lipid rafts isolated from mature CGNs in culture. The presence of PKA and CaMK-II 
in lipid raft membrane fractions was determined by Western blotting using rabbit anti-PKA (sc-28892) 
and rabbit anti-CaMK-II (sc-9035), with rabbit anti-caveolin-1 (sc-894) for the lipid raft protein marker 
caveolin-1. Fractions 1–5, which are enriched in lipid raft marker proteins caveolin-1 and H-Ras, are 
also enriched in cholesterol, as shown in previous works by our laboratory [8–10]. (A) PKA and 
CaMK-II are present in fractions 1–5 where lipid raft markers are also enriched, both in CGN survival 
medium MLocke’s K25 and also after 1 h incubation at 37 °C in a 5% CO2 culture chamber in 
proapoptotic MLocke’s K5 medium. The Western blot images shown are representative of the results 
obtained in experiments done with at least three different preparations of lipid rafts, as indicated in 
Materials and Methods. The same amount of lipid raft protein, 5 μg, was loaded into each lane in 
these experiments. The position of the molecular weight marker bands closest to the target proteins 
of the primary antibodies, i.e., caveolin-1 (~20 kDa), CaMK-II (~50 kDa), and PKA (~40 kDa), are 
shown at the left or right side of the corresponding PVDF membrane images. (B) Results of 
immunoprecipitation of cell lysates with caveolin-1, performed as indicated in Materials and 
Methods. The fraction of PKA and CaMK-II immunoprecipitated with caveolin-1 was calculated from 
a densitometry analysis of their bands in the Western blots and revealed using the primary and 
secondary antibodies indicated above, taking into account that while all precipitated samples were 
loaded into the corresponding lanes of the SDS-PAGE gels (IP), only a fraction of the total supernatant 
volume (S) was loaded into the gel lanes. The results shown in the table inserted in this panel are the 
average ± S.E. of triplicate experiments. 
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membrane fractions w s determined by Western blotting using rabbit anti-PKA (sc-28892) and rabbit
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2.3. PKA and CAMK-II Inhibitors Decrease the Phosphorylation Level of the β2 Subunit of LTCCs to the
Phosphorylation Levels Measured after CGN Treatment with MβCD and Also in Proapoptotic K5 Medium
The effects of pre-incubating CGNs with the PKA inhibitor H-89, the CaMKII inhibitor KN-93, and
the KN-93 analogue KN-92 (noninhibitor) for 15 min on the steady-state level of the phosphorylation of
the LTCC β2 subunit were measured by Western blotting using the antibody PCCb2-140AP (FabGennix
Inc.). The results show that the phosphorylation level of the β2 subunit of LTCCs of mature CGNs
in MLocke’s K25 is high, suggesting that LTCCs are largely phosphorylated in these experimental
conditions (Figure 3A). The results in Figure 3A also show that the ratio (p)LTCC/LTCC decreases
30 ± 5% when CGNs are treated with the PKA inhibitor H-89 and 45 ± 5% when CGNs are treated
with the CaMK-II inhibitor KN-93. Notably, the analogue of KN-93, KN-92, though not an inhibitor
of CaMK-II, affords a decrease of 30 ± 3% in the (p)LTCC/LTCC ratio, which is about 2/3 of the
decrease produced by KN-93 (Figure 3B). Taking into account the major role of LTCCs in controlling
the steady-state concentration of cytosolic calcium in CGNs [34,35,45] and that both KN-92 and KN-93
are potent inhibitors of calcium entry through LTCCs [46], we hypothesized that at the concentrations
of KN-93 and KN-92 used, these compounds can produce a large drop in CGN cytosolic calcium
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concentration, and this would elicit CaMK-II inhibition. This was confirmed by measuring the cytosolic
calcium concentration of Fura-2-loaded CGNs after the addition of KN-92 and KN-93 (Figure 3C).
The results show that (a) both produce a large decrease in the (340/380) ratio, from 1.0 ± 0.1 to
0.55 ± 0.05 for KN-93 and to 0.65 ± 0.05 for KN-92, values that are close to those attained after the
addition of the LTCC blocker nifedipine, 0.55 ± 0.05, and (b) there is a slower rate [Ca2+]i decrease
in CGN somas for KN-92 than for KN-93. It is worthy to note that low (340/380) ratio values
(close to 0.5) are also attained upon lowering the concentration of K+ in the extracellular medium to
5 mM [34,47]. Proapoptotic conditioning events develop as early as 1 h after changing these neurons
to a K5 medium [45,47–49]. Notably, the phosphorylation level of the β2 subunit of LTCCs after 1 h of
proapoptotic conditioning in MLocke’s K5 decreases by 65 ± 5% (Figure 3A). This decrease is higher
than that observed after incubation of CGNs in MLocke’s K25 for 15 min with the CaMK-II inhibitor
KN-93. However, the sum of the contributions of CaMK-II and PKA to the steady phosphorylation
level in MLocke’s K25 is 80 ± 10% (see above), a value that can fully account for the decrease in
phosphorylation of the β2 subunit of LTCCs observed after CGN treatment with MβCD or after 1 h in
MLocke’s K5.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 21 
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°C in a 5% CO2 culture chamber with 20 µM H-89, 30 µM KN-93, or in the absence of these inhibitors 
(K25 control), or after CGN incubation for 1 h at 37 °C in the 5% CO2 culture chamber in the 
proapoptosis MLocke’s K5 condition (K5). (B) CGNs in MLocke’s K25 were incubated for 15 min at 
37 °C in the 5% CO2 culture chamber with 30 µM KN-92, 30 µM KN-93, or in the absence of these 
inhibitors (K25 control). After SDS-PAGE (7.5% acrylamide), the proteins were transferred to PVDF 
membranes for Western blotting as indicated in Materials and Methods. For panel B, the PVDF 
membrane was stripped twice to remove primary antibodies—anti-β2 subunit of LTCCs and anti-
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10 µM nifedipine was added. Mature CGNs in culture were loaded with Fura-2, as indicated in the 
Materials and Methods section, and then changed to MLocke’s K25 buffer (37 °C) to start serial 340 
and 380 image acquisition. Data acquisition was done as indicated in the Materials and Methods 
section, with exposure times lower than 0.4 s at time intervals of 30 s. The 340/380 ratio of neuronal 
somas was measured using the region of interest (ROI) tool of the HCImage software. The 340/380 
ratio values shown are the average ± S.E. of experiments done with three different preparations of 
CGNs (n > 300 neuronal somas of fields taken from six plates for each experimental condition). 
Figure 3. H-89 and KN-93 decrease the phosphorylation of the β2 subunit of LTCCs to values measured
in proapoptotic MLocke’s K5. (A) CGNs in MLocke’s K25 were incubated for 15 min at 37 ◦C in a
5% CO2 culture chamber with 20 µM H-89, 30 µM KN-93, or in the absence of these inhibitors (K25
control), or after CGN incubation for 1 h at 37 ◦C in the 5% CO2 culture chamber in the proapoptosis
MLocke’s K5 condition (K5). (B) CGNs in MLocke’s K25 were incubated for 15 min at 37 ◦C i the
5% CO2 cultur chamber with 30 µM KN-92, 3 - 3 or in the absence of se inhibit rs (K25
control). After SDS-PAGE (7.5% acrylamide), the proteins were transf rred to PVDF membranes for
Western blotting as indicated in Materials and Methods. Fo panel B, th PVDF membrane was stripped
twice to remove primary antibodies—anti-β2 subunit of LTCCs and anti-LTCC α1C subunit—and used
afterward for β-actin detection. Th results shown in th se panels are representative of the results
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obtained in triplicate experiments with different CGN preparations. The position of the molecular
weight marker bands closest to the target proteins of the primary antibodies, i.e., β2 subunit of
LTCC, LTCC α1C subunit, and β-actin, are shown at the left or right side of the corresponding PVDF
membrane images. Western blots were revealed by exposure to autoradiography films for (A) and
with ChemiDocTM XRS+ from Bio-Rad for (B). The phosphorylation levels of the β2 subunit of LTCCs,
(p)β2LTCC/LTCC, shown in the bar graphs of panels A and B, were measured as indicated in the
legend for Figure 1 and are average results ± S.E. of triplicate experiments. (*) p < 0.05. (C) Time
dependence of population averages of the 340/380 ratio in neuronal somas before and after the addition
of 30 µM KN-93 (black-filled squares) or 30 µM KN-92 (white-filled squares) at the point indicated
by the first arrow. At the point indicated by the second arrow, 10 µM nifedipine was added. Mature
CGNs in culture were loaded with Fura-2, as indicated in the Materials and Methods section, and then
changed to MLocke’s K25 buffer (37 ◦C) to start serial 340 and 380 image acquisition. Data acquisition
was done as indicated in the Materials and Methods section, with exposure times lower than 0.4 s
at time intervals of 30 s. The 340/380 ratio of neuronal somas was measured using the region of
interest (ROI) tool of the HCImage software. The 340/380 ratio values shown are the average ± S.E. of
experiments done with three different preparations of CGNs (n > 300 neuronal somas of fields taken
from six plates for each experimental condition).
2.4. Treatment of CGNs with MβCD or with the PKA Inhibitor H-89 Lowers Steady-State [Ca2+]i to Values
Close to Those Attained in Proapoptotic K5 Medium
CGNs were treated with 5 mM MβCD for 1 h in serum-free DMEM:F12 medium (1:1),
supplemented as indicated in Materials and Methods, to experimentally assess the effect of CGN
treatment with MβCD on calcium entry through LTCCs. Then, the medium was replaced to remove
MβCD–cholesterol complexes, and CGNs were loaded with 5 µM Fura-2 AM. As we noticed that this
treatment with MβCD enhances the Fura-2 AM loading of CGNs, we used shorter times for loading
in these experiments, between 30 and 35 min. After CGN loading with Fura-2 AM, we measured
the cell viability as indicated in Materials and Methods and found that this treatment produces less
than a 10% loss of cell viability, i.e., a statistically nonsignificant loss of cell viability. The 340/380
ratio measurements show that the treatment with MβCD lowers the steady-state [Ca2+]i to values
approaching those obtained after the addition of nifedipine (Figure 4A,B).
Control experiments show that the 340/380 ratio of Fura-2-loaded CGNs in MLocke’s K25 is
steady for at least 30 min, yielding an average 340/380 ratio of 1.0 ± 0.1 (Figure 5B), as also shown in
previous works [9,34,47]. To evaluate the contribution of calcium entry through LTCCs to steady-state
[Ca2+]i, we used the specific blockers nifedipine and nimodipine. The addition of either of these
dihydropyridines produces a drop in the 340/380 ratio to a value of 0.55 ± 0.05 in less than 1 min after
adding the LTCC blockers nifedipine or nimodipine (Figure 5). This is close to the steady-state 340/380
ratio measured after changing CGNs to the proapoptotic K5 medium, 0.50 ± 0.05 (see below), and
this is consistent with the inactivation of LTCCs upon CGN plasma membrane polarization noticed
in earlier works. PKA and PKC have been reported as possible modulators of LTCC activity, as they
can affect Ca2+ influx through LTCCs [24,27]. As also shown in Figure 5, the addition of the PKA
inhibitor H-89 decreases the 340/380 ratio to 0.55 ± 0.05. Notably, after 15 min of the addition of
H-89, the 340/380 ratio reaches the steady-state value attained after the addition of the LTCC blockers
nifedipine and nimodipine (Figure 5). These results show that the inhibition of PKA produces a potent
inhibition of calcium entry through LTCCs in mature CGNs in MLocke’s K25 medium. In contrast, the
addition of 2 µM of the PKC inhibitor calphostin C does not have a statistically significant effect on the
steady 340/380 ratio, pointing out that in our experimental conditions, the PKC activity does not seem
to be relevant to the control of the steady-state [Ca2+]i in CGN soma.
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These results lead to the conclusion that the effects of H-89, KN-93, and KN-92 on the steady-state
[Ca2+]i in the somas of CGN in MLocke’s K25 are largely dominated by the inhibition of calcium entry
through LTCC.
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Figure 5. H-89 decreases CGN steady-state [Ca2+]i to values obtained upon the blockade of LTCCs by
nifedipine and nimodipine, while calphostin C has no effect. Mature CGNs in culture were loaded
with Fura-2, as indicated in the Materials and Methods section, and then changed to MLocke’s K25
buffer (37 ◦C) and treated with the indicated protein kinase inhibitors. (A) Representative pseudocolor
images of the same fields of selected CGN plates before (left-most column of images) and after 15 min
incubation (middle column of images) with 20 µM of the PKA inhibitor (H-89) or in the absence of
inhibitor (control) and 2 min after the addition of 10 µM nifedipine ost-H-89 (images in the right-most
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column). Pseudocolor scale for 340/380 ratio values: light blue, 0.5–0.6; green, 1.0–1.1. Scale bar =
10 µm. The white-filled arrows pointing toward Panel B indicate the approximate times at which these
images were captured. (B,C) Time dependence of population averages of the 340/380 ratio in neuronal
somas before and after the addition of the indicated protein kinase inhibitors after 350 s (at the point
indicated by the first arrow). The kinetic analysis of the 340/380 ratio of the somas of CGNs was done
for controls (vehicle DMSO addition, solid black squares) and for the addition of 20 µM H-89 (red solid
circles) and 2 µM calphostin C (blue down-triangles), inhibitors of PKA and PKC, respectively. Each
inhibitor was added to a different culture plate. At approximately 1350 s (at the point indicated by
the second arrow), 10 µM nifedipine (B) or 10 µM nimodipine (C) was added to the culture plates in
all conditions. Data acquisition and analysis were done after the selection of neuronal somas using
the region of interest (ROI) tool of the HCImage software, as indicated in the Materials and Methods
section, with exposure times lower than 0.4 s at time intervals of 30 s. The 340/380 ratio values shown
are the average± S.E. of experiments done with three different preparations of CGNs (n > 300 neuronal
somas of fields taken from six plates for each experimental condition).
2.5. Inhibition of PKA Alters the LTCC Response to Partial Depolarization of the Plasma Membrane in CGNs
In MLocke’s with 5 mM KCl, fluorescence imaging of CGNs loaded with Fura-2 yields a low
steady 340/380 ratio in the neuronal somas of 0.50 ± 0.05, i.e., [Ca2+]i ~40–50 nM (Figure 6A,B).
The same 340/380 ratio readings were obtained in this medium in the presence or absence of H-89
(PKA inhibitor) added to the plate 10 min before starting the measurements of cytosolic calcium
concentration (Figure 6A,B). However, H-89 largely impairs the kinetics of the [Ca2+]i response to
the addition of 20 mM KCl to the extracellular medium, which increases the extracellular KCl up
to 25 mM. In the controls for CGNs loaded with Fura-2, the addition of 20 mM KCl elicits biphasic
kinetics with a strong and fast rise in the 340/380 ratio until reaching values higher than 1.0—between
1.2 and 1.5 for most neuronal somas in the plates—followed by slower kinetics for the decay in the
340/380 ratio (t1/2 ≤ 2 min) until reaching values of approximately 0.95 ± 0.05 (Figure 6A,B), i.e.,
[Ca2+]i~150 ± 30 nM, which is within the range obtained for the somas of CGNs loaded with Fura-2
several minutes after changing the cells to MLocke’s K25 [34]. The pre-incubation of CGNs with H-89
for only 15 min largely attenuates the rise in the 340/380 ratio after the addition of 20 mM KCl to the
extracellular medium (Figure 6A,B). Noteworthy is that the steady-state 340/380 ratio attained after
several minutes reaches a value of 0.60 ± 0.05, which is very close to the (340/380) ratio measured
for the somas of control CGN plates before the addition of 20 mM KCl to the extracellular MLocke’s
medium. The blockade of the [Ca2+]i response by the inhibitor of PKA requires several minutes of
CGN pre-incubation, since only a slight attenuation of the strong and fast rise in the 340/380 ratio
is observed when the PKA inhibitor is added simultaneously with 20 mM KCl to the extracellular
MLocke’s medium (Figure 6C). This correlates with the change in the phosphorylation level of LTCCs
elicited by the PKA inhibitor H89 after only a 15 min pre-incubation (Figure 3). It is to be noted that a
15 min pre-incubation of Fura-2-loaded CGNs with 2 µM of the PKC inhibitor calphostin C before the
addition of 20 mM KCl has, at most, a weak effect that is statistically nonsignificant on the kinetics of
the [Ca2+]i response to the addition of 20 mM KCl to the extracellular medium.
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and thereafter treated as indicated below. (A) Representative pseudocolor images of the same fields of
selected CGN plates after 1 h in low-potassium MLocke’s K5 before (left) and 10 min after the addition
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starting the measurements of 340/380 ratios, cell plates were incubated for 10 min with 20 µM of
the PKA inhibitor (H-89, gray-filled circles). The results obtained for controls in the absence of these
inhibitors (addition of the solvent DMSO used to solubilize H-89) are shown with solid black squares.
(C) Population averages of 340/380 ratio measurements in neuronal somas before and after the addition
of 20 mM KCl (control, solid black squares) or 20 mM KCl plus 20 µM H-89 (gray-filled circles) at the
time indicated with a black arrow. For all the panels, each inhibitor was added to a different culture
plate. Data acquisition and analysis were done after the selection of neuronal somas using the region
of interest (ROI) tool of the HCImage software as indicated in the Materials and Methods section,
with exposure times lower than 0.4 s at time intervals of 30 s. The 340/380 ratio values shown are the
average ± S.E. of experiments done with three different preparations of CGNs (n > 300 neuronal somas
of fields taken from six cell plates for each experimental condition).
3. Discussion
The results of this work show that lipid rafts allow for more efficient control of the LTCC
phosphorylation level in mature CGNs in vitro. Here, it is shown that PKA and CaMK-II also associate
with caveolin-1-rich lipid rafts in the plasma membrane of CGN and that treatment with the lipid
raft-disrupting agent MβCD largely decreases the phosphorylation level of the β2 subunit of LTCCs
to levels observed in the presence of inhibitors of PKA and CaMK-II, and also to those observed
in the proapoptotic conditions attained by low potassium (5 mM) in the extracellular medium,
an experimental condition that inactivates LTCCs [33]. These effects of MβCD are observed at
concentrations that induce a large depletion of cholesterol in CGNs and before a significant loss of cell
viability. Consistently, the pretreatment of CGNs with MβCD and the removal of MβCD–cholesterol
complexes formed results in a decrease in the steady-state cytosolic [Ca2+]i in the neuronal somas;
the decrease is close to that induced by the LTCC blocker nifedipine, highlighting that MβCD treatment
leads to a large functional inactivation of LTCCs, even in the partial depolarizing conditions elicited
by 25 mM KCl in the extracellular medium. Taken together, our results strongly support the notion
that the disruption of lipid rafts impairs the activation of LTCCs by partial depolarizing conditions by
decreasing the phosphorylation of their β2 subunit by PKA and CaMK-II. Indeed, it is to be noted that
the initial rate and kinetic half-time of the decrease in [Ca2+]i produced by the CaMK-II inhibitor KN-93
are about 3-fold higher than those obtained for the noninhibitor analogue KN-92 (Figure 3C), despite
both displaying a potency similar as inhibitors of LTCC [46]. Moreover, a difference of ~2 min between
the half-time values of the kinetics of the decrease in [Ca2+]i by KN-92 and KN-93 can be accounted for
by the well-known slow kinetics of the loss of calcium-independent CaMK-II activity, which has been
reported to take place at a timescale of minutes in neurons [50]. As we showed in a previous work that
functional lipid rafts define the high-calcium sub-microcompartments near the plasma membrane of
mature CGNs [9], these results are also consistent with a stringent requirement for local Ca2+-dependent
activation of CaMK-II in the channel vicinity, as suggested by the blockade of CaMK-II-dependent
LTCC facilitation by the “fast” Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
(BAPTA) but not by the slow chelator ethylene glycol-bis(β-aminoethyl ether) N,N,N′,N′-tetraacetic acid
(EGTA) [51]. In addition, our results are in accordance with a previous work reporting the modulation
of the structural coupling between LTCCs and regulatory proteins by cholesterol in cardiomyocytes [52],
where the authors concluded that alterations in the current of LTCCs are mediated by MβCD.
The relevance of the sustained increase in [Ca2+]i produced by 25 mM KCl plasma membrane
depolarization to CGN survival is highlighted by the fact that, within the first 3 h after inducing
apoptosis in 5 mM KCl medium, cell death can be largely blocked by simply increasing the KCl
concentration of the extracellular medium to 25 mM [18,48], which promotes neuronal survival.
The results of this work show that in mature CGN cultures, the level of phosphorylation of the β2
subunit of LTCCs in a survival medium containing 25 mM KCl is significantly higher than that in
proapoptotic 5 mM KCl medium, thus uncovering a major role for the phosphorylation of the LTCC
β2 subunit in the activity of these calcium channels. Indeed, our results show that LTCC activity
accounts for nearly 85% of the steady-state increase in cytosolic calcium concentration in the CGN
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somas that is observed with the partial depolarization of the plasma membrane when extracellular
potassium rises from 5 mM (proapoptotic condition) to 25 mM (neuron survival condition) (see the
Supplementary Figure). This is in agreement with the major relevance of LTCC activity to the survival
of these neurons in culture which was noticed earlier [33,34,38], and it is also consistent with the low
level of L-glutamate detected in the extracellular medium when CGNs are in 25 mM KCl MLocke’s
medium [35]. Treatment of CGNs in 25 mM KCl MLocke’s medium with the PKA inhibitor H-89
decreases the steady-state cytosolic [Ca2+]i down to the values measured in the proapoptotic 5 mM
KCl MLocke’s medium in less than 15 min. Moreover, the effects of H-89 on the steady-state [Ca2+]i
in the somas of CGNs in MLocke’s K25 are largely dominated by the inhibition of calcium entry
through LTCCs. Noteworthy is that the sum of the decreases in the phosphorylation level of the
LTCC β2 subunit elicited by CaMK-II and PKA inhibitors correlates with the large decrease in the
phosphorylation level of the LTCC β2 subunit resulting from the proapoptotic conditioning of CGNs.
Thus, the phosphorylation of the β2 subunit can largely account for the activation of LTCCs by partial
plasma membrane depolarization induced by the presence of 25 mM KCl in the extracellular medium.
In contrast, we found that the steady-state cytosolic [Ca2+]i is not significantly altered by calphostin C,
an inhibitor of PKC, excluding a major role for this protein kinase in the control of cytosolic calcium
homeostasis in mature CGNs in culture.
Our results also indicate that the activity of these calcium channels plays the leading role in
modulating the excitability threshold of CGNs. Under our experimental conditions in culture and
in the absence of neurotrophic factors, the contribution of other calcium channels and of NMDAr
to maintain a sustained level of cytosolic [Ca2+]i and thus promoting neuronal survival is only very
minor for mature CGNs [34,35] (see also the Supplementary Figure). In the brain, nearly 80% of
the α-subunits of LTCCs belong are the CaV1.2 (α1C) subtype, and 10–25% are the subtype CaV1.3
(α1D) [53], while in cerebellar granule neurons, CaV1.2 accounts for 89% and CaV1.3 for 11% of LTCC
transcripts [54]. Interestingly, the hyperactivation of CaV1.2 LTCCs by CaMK-II is implicated in Timothy
Syndrome, a multiorgan human genetic disorder whose symptoms include mental retardation and
cardiac disease [55,56], and the excessive activation of CaV1.3 LTCCs is implicated in the loss of dendritic
spines following dopamine depletion in animal models of parkinsonism [57]. Thus, the activity of
LTCCs plays a major role in the fine-tuning of CGN excitability, as cytosolic [Ca2+]i plays a major role in
neuronal secretory activity—both the basal secretory activity and the minimum stimuli needed to elicit
a neuronal response. Indeed, it has been shown that LTCCs play a relevant role in NMDAr-independent
long-term potentiation [58]. Therefore, the impairment of LTCC activity by MβCD is likely to be a
molecular mechanism underlying the neurological disorders induced by this compound.
The altered LTCC response to a partial depolarization of the plasma membrane in CGNs upon
inhibition of PKA, as reported in this work, lends support to a major role for this protein kinase in
the normal functioning of granule neurons in the cerebellar cortex. Several β subunits of LTCCs
are expressed in rat brain cerebellum [59], namely, β2, β3, and β4, but not the isoform β1, with
the β4 isoform of the β subunit showing higher levels of expression. However, it has been shown
that activated/autophosphorylated CaMK-II binds to the β2 isoform, but it does not bind to β3 or
to β4 [27]. Also, CaMK-II coimmunoprecipitates with forebrain LTCCs that contain CaV1.2α1 and
β1 or β2 subunits, but CAMK-II is not detected in LTCC complexes containing β4 subunits [60].
In addition, it has been demonstrated that LTCC modulation by PKA is due to β2 and α1c subunit
phosphorylation [23,24]. Mutations of serine 478 (Ser478) and serine 479 (Ser479) from the β2 subunit
resulted in the complete inhibition of the PKA-induced increase in calcium currents through LTCCs [23].
On these grounds, we selected for this study an antibody produced by FabGennix Inc. (PCCb2-140AP),
using as the immunogen a synthetic peptide with the amino acid sequence “ecs kqr s(p)rh kskdry c”
which is located near the C-terminal end of the rat β2 subunit of LTCCs and which is absent in β3 and
β4 isoforms. This amino acid sequence is also very close to other phosphorylation sites reported for
PKA and CaMK-II in the β2 subunit of LTCCs, namely, Ser478, Ser479, and Thr498 [23,26,27]. Moreover,
the two serines present in this sequence, which correspond to Ser566 and Ser570 in rat’s β2 subunit
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(Uniprot: Q8VGC3), are also potential sites for phosphorylation by both kinases, particularly Ser570,
which fulfills the criteria for a consensus phosphorylation site of CaMK-II. Indeed, Grueter et al. [27]
reported a stoichiometry of 6 phosphorylation sites targeted by CaMK-II per mol of β2 subunits. Thus,
our results can be rationalized in terms of phosphorylation of the β2 subunit of LTCCs at the serines
present in the amino acid sequence “ecs kqr s(p)rh kskdry c” or in terms of immunoreactivity of the
PCCb2-140AP antibody with the vicinal phosphorylation sites, i.e., Ser478(P) and/or Ser479(P) and/or
Thr498(P). It is to be noted that both CaMK-II and PKA have been reported to act synergistically to
increase the calcium current intensity through LTCCs in cardiac myocytes [61].
In conclusion, the results of this work reveal a critical role for the phosphorylation of the β2
subunit of LTCCs by the CaMK-II and PKA associated with caveolin-1-rich lipid rafts to maintain
LTCC activity in CGNs grown in culture. In addition, our results show that cholesterol depletion by
MβCD decreases the steady-state [Ca2+]i down to the sustained proapoptotic low [Ca2+]i range. This is
summarized in the scheme drawn in Figure 7. Whether pharmacological overstimulation of PKA or
CaMK-II can counteract the decrease in the phosphorylation of the LTCC β2 subunit and the decrease
in steady-state [Ca2+]i upon partial lipid raft disruption remain to be settled.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  14 of 21 
 
[23,24]. Mutations of serine 478 (Ser478) and serine 479 (Ser479) from the β2 subunit resulted in the 
complete inhibition of the PKA-induced increase in calcium currents through LTCCs [23]. On these 
grounds, we selected for this study an antibody produced by FabGennix Inc. (PCCb2-140AP), using 
as the immunogen a synthetic peptide with the amino acid sequence “ecs kqr s(p)rh kskdry c” which 
is located near the C-terminal end of the rat β2 subunit of LTCCs and which is absent in β3 and β4 
isoforms. This amino acid sequence is also very close to other phosphorylation sites reported for PKA 
and CaMK-II in the β2 subunit of LTCCs, namely, Ser478, Ser479, and Thr498 [23,26,27]. Moreover, 
the two serines present in this sequence, which correspond to Ser566 and Ser570 in rat’s β2 subunit 
(Uniprot: Q8VGC3), are also potential sites for phosphorylation by both kinases, particularly Ser570, 
which fulfills the criteria for a consensus phosphorylation site of CaMK-II. Indeed, Grueter et al. [27] 
report d a stoichiometry of 6 phosphorylation sites targeted by CaMK-II per mol of β2 subunits. Thus, 
our results can be rationaliz d in terms of phosphorylation of the β2 subunit of LTCCs at the serines 
present in the amino acid sequence “ecs kqr s(p)rh kskdry c” or in terms of immunoreactivity of the 
PCCb2-140AP antibody with the vicinal phosphorylation sites, i.e., Ser478(P) and/or Ser479(P) and/or 
Thr498(P). It is to be noted that both CaMK-II and PKA have been reported to act synergistically to 
increase the calcium current intensity through LTCCs in cardiac myocytes [61]. 
In conclusion, the results of this work reveal a critical role for the phosphorylation of the β2 
subunit of LTCCs by the CaMK-II and PKA associated with caveolin-1-ric  lipid raft  to maintain 
LTCC ctivi y in CGNs grown in culture. In addition, our results show that cholesterol depletio  by 
MβCD decreases the steady-state [Ca2+]i down to the sustained proapoptotic low [Ca2+]i range. This 
is summarized in the scheme drawn in Figure 7. Whether pharmacological overstimulation of PKA 
or CaMK-II can counteract the decrease in the phosphorylation of the LTCC β2 subunit and the 
decrease in steady-state [Ca2+]i upon partial lipid raft disruption remain to be settled.  
 
Figure 7. Schematic diagram summarizing the major results and conclusions of this work. The rise in 
the steady-state [Ca2+]i in neuronal somas up to the values needed for CGN survival induced by the 
increase in extracellular K+ from 5 to 25 mM is mediated by CaMK-II and PKA phosphorylation of the 
β2 subunit of LTCCs clustered in caveolin-1-rich lipid rafts. The gray contour filled with thin vertical 
lines represents caveolin-1-rich lipid rafts containing LTCC, CaMK-II, and PKA. The inhibitors of 
CaMK-II (KN-93) and of PKA (H-89) and the lipid raft-disrupting compound MβCD decrease the 
levels of phosphorylated LTCC, (P)-β2LTCC, to the values measured in proapoptotic 5 mM KCl 
medium, resulting in the inactivation of LTCCs and a sustained proapoptotic low steady-state [Ca2+]i 
Figure 7. Schematic diagram sum arizing the j results and conclusions of this work. The rise in
the steady-state [Ca2+]i in neuronal somas up to the values needed for CGN survival induced by the
increase in extracellular K+ from 5 to 25 mM is mediated by CaMK-II and PKA phosphorylation of the
β2 subunit of LTCCs clustered in caveolin-1-rich lipid rafts. The gray contour filled with thin vertical
lines represents caveolin-1-rich lipid rafts containing LTCC, CaMK-II, and PKA. The inhibitors of
CaMK-II (KN-93) and of PKA (H-89) and the lipid raft-disrupting compound MβCD decrease the levels
of phosphorylat d LTCC, (P)-β2LTCC, to the values me sured in proapoptotic 5 mM K l medium,
resulting in the inactivation of LTCCs and a sustained proapoptotic low steady-state [Ca2+]i in neuronal
somas. For the sake of simplicity, other proteins present in caveolin-1-rich lipid rafts of mature CGNs
(see, e.g., [8–10,49,62]) are not included in this schematic diagram.
4. Materials and Methods
4.1. Preparation of Rat Cerebellar Granule Neurons (CGNs)
CGNs were obtained from dissociated cerebella of 7-days-old Wistar rats as described
previously [8,9,34,47–49,62,63]. All animal handling was performed in accordance with Spanish
regulations and approved by the Ethical Committee of the University of Extremadura. Briefly, cells
were plated in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% heat-inactivated
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fetal bovine serum, 5 mM glucose, 19.63 mM KCl, 3.7 ng/mL insulin, 7 µM 4-aminobenzoic acid,
50 U/mL penicillin, 25 U/mL streptomycin, 0.91 mM pyruvate, and 2 mM glutamine on 35 mm diameter
dishes (Corning, NY, USA) coated with poly-D-lysine at a density of 2.5 × 106 cells/dish. Cultures
were maintained at 37 ◦C in a humidified atmosphere of 95% air/5% CO2. Cytosine arabinofuranoside
(10 µM) was added to fresh culture medium 48 h after plating to prevent the replication of non-neuronal
cells. Seven days after plating, the culture medium was replaced with the serum-free DMEM:F12
medium (1:1) supplemented with 12.5 mM glucose, 20.82 mM KCl, 5 µg/mL insulin, 0.1 mg/mL
apo-transferrin, 20 nM progesterone, 50 U/mL penicillin, 25 U/mL streptomycin, 0.1 mg/mL pyruvate,
and 2 mM L-glutamine. Mature CGNs at 9–10 days in vitro were used in all the experiments.
Buffer composition used in this work is as follows: (a) MLocke’s K25 buffer (pH 7.4 at 37 ◦C):
4 mM NaHCO3, 10 mM Tricine, 5 mM glucose, 2.3 mM CaCl2, 1 mM MgCl2, and 134 mM NaCl/25 mM
KCl; (b) MLocke’s K5 buffer (pH 7.4 at 37 ◦C): 4 mM NaHCO3, 10 mM Tricine, 5 mM glucose, 2.3 mM
CaCl2, 1 mM MgCl2, and 154 mM NaCl/5 mM KCl.
Cell viability was experimentally assessed by measuring the amount of colored formazan by
the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as in previous
works [9,34,47,48,63].
4.2. Measurement of the Intracellular Free Ca2+ Concentration ([Ca2+]i)
[Ca2+]i was measured as in previous works [9,15,34,35,47,63]. Briefly, CGNs were loaded
with Fura-2 by incubation for 60 min in DMEM-F12 containing, unless stated otherwise, 5 µM
Fura-2-acetoxymethyl ester (Fura-2 AM) and 0.025% Pluronic-F127 at 37 ◦C. Afterward, CGNs were
washed and the culture dish placed in a thermostatically controlled plate (Warner Instrument Co.,
Hamden, CT, USA) of a Nikon Diaphot 300 (Tokyo, Japan) inverted microscope, equipped with an
epifluorescence attachment and excitation filter wheel. Digital images with 340 and 380 nm excitation
filters were taken with a Hamamatsu Orca-R2 CCD camera (binning mode 2 × 2) and Lamdba
10–2 filter wheel controller, and images were subsequently analyzed with HCImage software. Data
acquisition and analysis were done after the selection of the neuronal somas using the region of interest
(ROI) tool of this software. The data of 340/380 ratios are presented as population averages, and the
total number of neuronal somas averaged in each experimental condition are indicated in the legends
for the figures. A value of 224 nM was used for the dissociation constant of the Fura-2/Ca2+ complex
to obtain the [Ca2+]i values reported in this work, as in previous works [34,35].
4.3. CGN Cell Lysates and Western Blotting
Cell lysates used for controls and specific treatments were obtained from CGN cultures after a
2000× g centrifugation for 2 min at 4 ◦C in a refrigerated Eppendorf microcentrifuge followed by pellet
resuspension in lysis buffer (25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 5 mM
NaVO3, and 0.25% Triton X-100, supplemented with the Roche Biochemicals protease inhibitor cocktail
COMPLETE). Using Bradford’s method, we determined the protein concentration of cell lysates and
samples for running on an SDS-PAGE gel for Western blotting analysis.
In an SDS-PAGE gel at a concentration of 7.5, 10.4, or 12% acrylamide, for the same protein of
interest, a certain amount of CGN lysate or lipid raft fraction was loaded per lane, ranging between
5 and 20 µg of protein in different gels; then, we transferred the gel to PVDF or nitrocellulose
membranes with a 0.2 and 0.45 µm average pore size, respectively (Trans-BloT TransferMedium,
BioRad, Hercules, CA, USA). Depending on the protein of interest, membrane blocking was carried out
with 5% (w/v) non-fat dry milk or 5% bovine serum albumin, both in phosphate-buffered saline (PBS)
supplemented with 0.05% polyoxyethylenesorbitan monolaurate (PBST). Before incubation with the
primary antibody, membranes were washed three times with PBST. The immunodetection of proteins
was performed with their specific primary antibody at a dilution of 1:100 in PBST. After incubation
with the first antibody overnight, membranes were washed six times with PBST and incubated for
1 h at room temperature with the secondary IgG antibody conjugated with horseradish peroxidase.
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Secondary anti-rabbit IgG–horseradish peroxidase (Sigma A0545, Sigma-Aldrich, St. Louis, MI, USA)
or anti-mouse IgG–horseradish peroxidase (Pierce-1858413) was used at a dilution of 1:25,000 and
1:5000 in PBST, respectively. Again, we washed the membrane six times with PBST followed by
incubation for 3 min with Super-Signal West Dura Substrate (Pierce). Western blots were revealed by
exposure to an Amersham Hyperfilm MP autoradiography film (GE Healthcare, UK) or with Bio-Rad
ChemiDocTM XRS+. Then, membranes were treated under continuous stirring at room temperature
with the following stripping buffers: (1) 10 min with 0.2 M glycine/0.5 M NaCl brought to pH 2.8
with acetic acid and (2) 10 min with 0.5 M acetic acid/0.5 M NaCl at pH 2.5. After washing with
distilled water for 10 min, membranes were blocked with 3% bovine serum albumin in PBST and
treated as indicated above to quantify β-actin to monitor the protein load, using mouse anti-β-actin
(Sigma-Aldrich-A1978, 1:100 dilution) as the primary antibody and anti-mouse IgG–horseradish
peroxidase (Pierce-1858413, 1:5000 dilution) as the secondary antibody.
4.4. Lipid Raft Preparation
CGN lipid rafts were isolated as indicated in previous works [8–10], except that all the buffers
were supplemented with the phosphatase inhibitors NaF and NaVO3. Briefly, sucrose was added
to cell lysates to obtain a 41% concentration and then loaded over two layers of sucrose: 125 µL of
35% sucrose and 500 µL of 16% sucrose, prepared in 25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 50 mM NaF, and 5 mM NaVO3. For lipid raft isolation, samples were centrifuged for 5 h at 4 ◦C
in an SW60 rotor at 256,000× g for the average radius, and 10 fractions were collected (from the top to
the bottom, fractions 1–10). Protein concentration was determined using the Bradford protein assay.
Samples were analyzed by Western blotting as described above.
4.5. Immunoprecipitation
Immunoprecipitation was carried out using the ImmunoCruzTM IP/WB Optima system of Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA) following the instructions given in their technical
data sheets. Briefly, complexes between the matrix and antibodies were prepared as follows. In an
Eppendorf tube, 5 µg of anti-caveolin-1 (sc-894) was mixed with 50 µL of the appropriate matrix
(IgG rabbit) and 500 µL of Tris-buffered saline. After 1 h incubation in a tube-rotor with continuous
shaking, the matrix was precipitated by 30 s centrifugation at 4 ◦C at 16,100× g in a refrigerated
Eppendorf microcentrifuge 5415R. The supernatant was removed, and the precipitated matrix was
subjected to three washes with 500 µL of Tris-buffered saline by 30 s centrifugation at 4 ◦C at 16,100× g
in a refrigerated Eppendorf microcentrifuge in each washing step. Before immunoprecipitation,
the cell lysates of CGNs were centrifuged at 500× g for 10 min to remove nuclei and cell debris.
Then, cell lysates were treated with 1% Triton-X100 for 30 min with mild stirring, and 400 µg of
protein lysate was added to the tube containing the matrix/antibody complex, prepared as indicated
above, and incubated overnight at 4 ◦C with continuous shaking in a tube-rotor. The matrix was
precipitated by 30 s centrifugation at 16,100× g and 4 ◦C, and the supernatant was carefully removed.
The precipitated matrix was resuspended in Tris-buffered saline and centrifuged again at 16,100× g
and 4 ◦C for a more complete removal of the remaining supernatant. This washing step was repeated
three times. Supernatants and washed matrix precipitate were mixed with standard sample buffer for
SDS-electrophoresis, boiled for 5 min, and loaded onto SDS-PAGE gels. Samples were analyzed by
SDS-PAGE followed by Western blotting as indicated above.
4.6. Measurement of Cholesterol Content in Cell Lysates
To quantify the extent of cholesterol removal by treatment with MβCD, we treated CGNs with
0, 5, 10, and 20 mM MβCD for 15 min in MLocke’s K25 buffer. After the treatment, the supernatant
was removed, and CGNs were carefully lysed, as indicated above. Cell lysates were homogenized by
50–60 passages through hypodermic needles, stainless steel gauge 26 of 1/2 inch length. The protein
content of these cell lysates was measured using the Bradford assay, and their cholesterol content
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was measured using a standard assay with Amplex RedTM (Invitrogen Life Sciences Technologies
–Thermo Fisher Scientific). The fluorescent product of oxidation of Amplex RedTM, resorufin, was
measured with a Perkin-Elmer 650–40 fluorimeter operated in ratio mode, with a fixed excitation
wavelength at 530 nm and emission wavelength at 590 nm, with 10/10 excitation/emission slits.
Amplex Red 50 µM was added to the assay buffer (pH 7.0): 2-{[2-hydroxy-1,1-bis(hydroxymethyl)
ethyl]amino} ethanesulfonic acid (TES) 50 mM, NaCl 100 mM, EDTA 0.1 mM in the presence of
horseradish peroxidase 0.2 U/mL. Cholesterol oxidase 1 U/mL was added, and fluorescence was
recorded for 20 min at 25 ◦C until the intensity reached a plateau.
4.7. CGN Treatments
In all experiments with proapoptotic low-potassium conditions, CGN plates were treated with
MLocke’s K5 buffer for 1 h at 37 ◦C, 5% CO2. In experiments performed in low potassium, CGN plates
loaded with Fura-2 AM were incubated for 15 min with H-89 (PKA inhibitor) at 37 ◦C, 5% CO2, before
image acquisition for [Ca2+]i measurements.
To study the phosphorylation levels of the β2 subunits of LTCC after protein kinase inhibition,
we treated CGN plates for 15 min at 37 ◦C and 5% CO2 with 20 µM H-89 to inhibit PKA and 30 µM
KN-93 to inhibit CaMK-II. These plates were lysed as previously described.
To study the effect of cholesterol extraction on the phosphorylation levels of LTCCs, CGNs were
treated for 15 min with 1 mM and 5 mM methyl-β-cyclodextrin (MβCD), a well-known cell-cholesterol
sequestering compound, in MLocke’s K25 buffer. MβCD concentrations were selected taking into
account our previous studies of cell viability [11]. Finally, to study the effect of cholesterol extraction on
[Ca2+]I, CGNs were treated with 5 mM MβCD in serum-free DMEM:F12 medium (1:1), supplemented
as indicated before, and, after 1 h treatment, CGNs were washed and loaded with Fura-2 AM for
measurements of [Ca2+]i. In this latter case, the incubation of CGNs with MβCD could not be
carried out simultaneously with Fura-2 AM nor with preloaded cells, since the treatment of CGNs for
30–45 min with MβCD produces a large release of Fura-2 from CGNs to the extracellular medium.
4.8. Chemicals and Reagents
Primary antibodies: rabbit anti-LTCC α1C subunit (sc-25686), rabbit anti-rabbit PKA (sc-28892),
rabbit anti-CaMK-II (sc-9035), and rabbit anti-caveolin-1 (sc-894) were supplied by Santa Cruz
Biotechnology (Santa Cruz, CA, USA);. rabbit anti-p-β2 subunit of LTCCs (PCCb2-140AP) was
supplied by FabGennix Inc. (Frisco, TX, USA); and mouse anti-β-actin (A1978) was supplied by
Sigma-Aldrich (Spain office). All these antibodies were used in the dilution range recommended
in their technical sheets and tested for the detection of molecular weight bands expected for their
corresponding proteins with whole CGN lysates before use in the experiments of this work. Western
blots reagents and anti-rabbit IgG–horseradish peroxidase was supplied by Sigma-Aldrich, and
anti-mouse IgG–horseradish peroxidase and SuperSignal West Dura Extended Duration Substrate
were supplied by Pierce (Rockford, IL, USA). KB-7943 and ω-conotoxin MVIIC were purchased from
Tocris Bioscience (Bristol, UK). MβCD, MK-801, nifedipine, nimodipine, and the specific protein kinase
inhibitors H-89 (B1427), KN-93 (K1385), and calphostin C (C6303) were supplied by Sigma-Aldrich
(Spain office). The ImmunoCruzTM IP/WB Optima B system (sc-45039) and KN-92 (sc-311369) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Fura-2 AM and Amplex RedTM from
Invitrogen Life Sciences Technologies were supplied by Thermo Fisher Scientific (Spain office). All other
reagents and chemicals were of analytical grade from Sigma-Aldrich (Spain office) or Roche-Merck
(Darmstadt, Germany).
4.9. Statistical Analysis
Results are expressed as the mean± standard error (S.E.). Statistical analysis was carried out by the
Mann–Whitney non-parametric test. A significant difference was accepted at the p < 0.05 level. All the
results were confirmed with duplicate measurements of at least three different CGN preparations.
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Abbreviations
[Ca2+]i intracellular free calcium concentration
CaMK-II calcium/calmodulin-dependent protein kinase II
CGN cerebellar granule neurons
DMEM Dulbecco’s modified Eagle medium
EDTA ethylenediamine tetraacetic acid
Fura-2 AM Fura-2-acetoxymethyl ester
LTCC L-type calcium channels
MβCD methyl-β-cyclodextrin
NMDAr, N-methyl D-aspartate receptor
PBS phosphate-buffered saline
PBST
PBS supplemented with 0.05% polyoxyethylenesorbitan monolaurate
(Tween 20)
PKA protein kinase A
PKC protein kinase C
VGCCs voltage-gated calcium channels.
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